阿柏西普用于治疗卡恩斯-塞尔综合征的色素性视网膜病变？ - Suppr

Suppr

超能文献

Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?

作者信息

Finsterer Josef

机构信息

Neurology Neurophysiology Center, Postfach 20, 1180, Vienna, Austria.

出版信息

Doc Ophthalmol. 2025 Jun;150(3):197-198. doi: 10.1007/s10633-025-10022-5. Epub 2025 May 20.

DOI:10.1007/s10633-025-10022-5

PMID:40389721

Abstract

摘要

相似文献

Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?

Doc Ophthalmol. 2025 Jun;150(3):197-198. doi: 10.1007/s10633-025-10022-5. Epub 2025 May 20.

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

Kearns-Sayre syndrome with a phenocopy of choroideremia instead of pigmentary retinopathy.

Neurology. 1993 Jan;43(1):218-21. doi: 10.1212/wnl.43.1_part_1.218.

NEW OBSERVATIONS REGARDING THE RETINOPATHY OF GENETICALLY CONFIRMED KEARNS-SAYRE SYNDROME.

Retin Cases Brief Rep. 2018;12(4):349-358. doi: 10.1097/ICB.0000000000000503.

Kearns-Sayre syndrome case. Novel 5,9 kb mtDNA deletion.

Mol Genet Genomic Med. 2023 Jan;11(1):e2059. doi: 10.1002/mgg3.2059. Epub 2022 Oct 1.

[Kearns-Sayre syndrome: ophthalmic manifestations].

An Pediatr (Barc). 2015 Jan;82(1):e151-3. doi: 10.1016/j.anpedi.2014.05.012. Epub 2014 Nov 20.

Ophthalmologic school-based screening revealing Kearns-Sayre syndrome: a case report.

Pan Afr Med J. 2022 Mar 18;41:226. doi: 10.11604/pamj.2022.41.226.33085. eCollection 2022.

Kearns Sayre Syndrome--case report with review of literature.

Indian J Pediatr. 2012 May;79(5):650-4. doi: 10.1007/s12098-011-0618-3. Epub 2012 Jan 10.

Anesthetic management of Kearns-Sayre syndrome. Case report.

Rev Esp Anestesiol Reanim (Engl Ed). 2021 Apr;68(4):232-234. doi: 10.1016/j.redar.2020.04.007. Epub 2020 Nov 5.

本文引用的文献

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis.

Sci Rep. 2024 Nov 16;14(1):28266. doi: 10.1038/s41598-024-78596-9.

mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.

EMBO Mol Med. 2018 Jun;10(6). doi: 10.15252/emmm.201708262.

Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.

Ophthalmology. 2016 Jul;123(7):1511-20. doi: 10.1016/j.ophtha.2016.02.046. Epub 2016 Apr 12.

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?

Doc Ophthalmol. 2025 Jun;150(3):197-198. doi: 10.1007/s10633-025-10022-5. Epub 2025 May 20.

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

Kearns-Sayre syndrome with a phenocopy of choroideremia instead of pigmentary retinopathy.

Neurology. 1993 Jan;43(1):218-21. doi: 10.1212/wnl.43.1_part_1.218.

NEW OBSERVATIONS REGARDING THE RETINOPATHY OF GENETICALLY CONFIRMED KEARNS-SAYRE SYNDROME.

Retin Cases Brief Rep. 2018;12(4):349-358. doi: 10.1097/ICB.0000000000000503.

Kearns-Sayre syndrome case. Novel 5,9 kb mtDNA deletion.

Mol Genet Genomic Med. 2023 Jan;11(1):e2059. doi: 10.1002/mgg3.2059. Epub 2022 Oct 1.

[Kearns-Sayre syndrome: ophthalmic manifestations].

An Pediatr (Barc). 2015 Jan;82(1):e151-3. doi: 10.1016/j.anpedi.2014.05.012. Epub 2014 Nov 20.

Ophthalmologic school-based screening revealing Kearns-Sayre syndrome: a case report.

Pan Afr Med J. 2022 Mar 18;41:226. doi: 10.11604/pamj.2022.41.226.33085. eCollection 2022.

Kearns Sayre Syndrome--case report with review of literature.

Indian J Pediatr. 2012 May;79(5):650-4. doi: 10.1007/s12098-011-0618-3. Epub 2012 Jan 10.

Anesthetic management of Kearns-Sayre syndrome. Case report.

Rev Esp Anestesiol Reanim (Engl Ed). 2021 Apr;68(4):232-234. doi: 10.1016/j.redar.2020.04.007. Epub 2020 Nov 5.

本文引用的文献

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Prevalence of diabetic retinopathy and its associated risk factors among adults in Ethiopia: a systematic review and meta-analysis.

Sci Rep. 2024 Nov 16;14(1):28266. doi: 10.1038/s41598-024-78596-9.

mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.

EMBO Mol Med. 2018 Jun;10(6). doi: 10.15252/emmm.201708262.

Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.

Ophthalmology. 2016 Jul;123(7):1511-20. doi: 10.1016/j.ophtha.2016.02.046. Epub 2016 Apr 12.

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302.